Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Where FDA Is Paying The Most Attention: Drug Safety Advisory Committee Had The Most Meetings In 2010

Executive Summary

FDA’s ongoing efforts to ramp up its focus on drug safety are being borne out at the advisory committee level, which saw a doubling in the number of meeting days for the Drug Safety and Risk Management Advisory Committee in 2010.

You may also be interested in...



In With The Old? 2013 To Mark Rebirth Of CDER’s Pharmacy Compounding, Medical Imaging AdComms

FDA has signaled that it will re-form its Pharmacy Compounding Drugs Advisory Committee, which was dissolved in 2002, as it deals with an ongoing meningitis outbreak related to compounded steroid injections. 2012 proved to be another busy year for the Oncologic Drugs Advisory Committee, but the full drug safety/risk management panel saw a significantly lighter workload than in recent years.

FDA Approving More Novel Drugs Without Advisory Committee Review

The Center for Drug Evaluation and Research is becoming more comfortable approving new molecular entities and novel biologics without first seeking the views of its outside experts. In 2011, 13 of the 30 novel therapeutics cleared did not undergo advisory committee scrutiny beforehand.

Pharmacovigilance Feeds EMA’s Transparency Drive

The scandal surrounding the withdrawal of Servier’s diabetes drug Mediator (benfluorex) continues to rock the French medical establishment, but it also has drawn attention to the issue of regulators' transparency more broadly – including at the European Medicines Agency.

Related Content

Topics

UsernamePublicRestriction

Register

PS053019

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel